|Bid||0.00 x 1200|
|Ask||0.00 x 1000|
|Day's range||217.72 - 217.94|
|52-week range||69.05 - 217.94|
|PE ratio (TTM)||N/A|
|Earnings date||8 Aug 2018 - 13 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||176.30|
On a per-share basis, the Bannockburn, Illinois-based company said it had a loss of $6.20. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
CHICAGO, May 03, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today reported financial results for the first quarter ended March 31, 2018, recent corporate highlights and upcoming milestones. “Throughout the first quarter and in recent weeks, we have made significant progress in executing against our strategic plan and are quite pleased that Novartis, with its pending acquisition of the company, recognizes the value that the AveXis team has created,” said Sean Nolan, President and Chief Executive Officer of AveXis. “Data presented recently at the American Academy of Neurology from both the Type 1 Phase 1 and STR1VE studies highlight the clinically transformative, durable and consistent response of AVXS-101.
CHICAGO, May 01, 2018-- AveXis, Inc., a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that ...
AveXis, Inc. (AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that the first patient has been dosed in a Phase 3 trial evaluating AVXS-101 in pre-symptomatic patients with spinal muscular atrophy (SMA) Types 1, 2 and 3 (SPRINT). “Treating SMA as early as possible is critically important in order to rescue motor neurons before they are permanently lost. SPRINT enables us to understand how intervening in pre-symptomatic infants with AVXS-101 may impact clinical outcomes, including milestone development such as functional sitting, standing without support and walking,” said Dr. Sukumar Nagendran, Chief Medical Officer of AveXis.
–A mean increase in CHOP-INTEND of 17.3 was observed at three months post gene therapy in SMA Type 1 U.S. pivotal trial–. –All patients in the therapeutic dose cohort in the Phase 1 trial were alive and ...
NEW YORK , April 24, 2018 /PRNewswire/ -- ADT Inc. (ADT) Lifshitz & Miller announces investigation into possible securities law violations in connection with ADT's IPO. If you are an ADT investor, and ...
The following statement is being issued by Levi & Korsinsky, LLP:
BERWYN, Pa. , April 19, 2018 /PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of AveXis, Inc. ("AveXis" or the "Company") (NASDAQ: AVXS) ...
NEW YORK , April 19, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
CHICAGO, April 19, 2018-- AveXis, Inc., a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced ...
Novartis (PFE) to buy AveXis for $8.7 billion. Merck's (MRK) Keytruda succeeds in another key lung cancer study. AbbVie's (ABBV) upadacitinib met endpoints in the 4th phase III study from its SELECT program.
With the announcement of Novartis (NVS) acquiring AveXis, a clinical stage gene therapy company, several companies have started to develop the therapy with many of them having promising candidates in their pipelines.
Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.
Investors need to pay close attention to AveXis (AVXS) stock based on the movements in the options market lately.
NEW YORK, April 11, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of AveXis Inc. ("AVXS" or the "Company") (AVXS) in connection with the proposed acquisition of the Company by Novartis AG ("Novartis"). Under the terms of the acquisition agreement, the Company's shareholders will receive $218.00 in cash for each AVXS share they own. WeissLaw is investigating whether AVXS's Board acted to maximize shareholder value prior to entering into the agreement. Notably, the deal is a strategic transaction which will catapult Novartis into leadership in the field of gene therapy and neuroscience, granting Novartis access to AVXS' gene therapy pipeline and the Company's portfolio of gene therapy treatments.